Intraoperative Radiation Therapy as a Safe Alternative to Whole Breast Radiation for Treatment of Minimally Invasive Breast Cancers: A Retrospective Cohort Study
Restricted accessResearch articleFirst published online February, 2024
Intraoperative Radiation Therapy as a Safe Alternative to Whole Breast Radiation for Treatment of Minimally Invasive Breast Cancers: A Retrospective Cohort Study
Intraoperative radiation therapy (IORT) in select populations is a viable alternative to whole breast radiation therapy (WBRT) in the treatment of biopsy-proven localized invasive and non-invasive breast cancer. We aim to assess recurrence and complication rates following IORT in lumpectomy patients at a community hospital in Baltimore City.
Methods
An IRB-approved retrospective cohort study was conducted on consecutive cases of lumpectomy with IORT from 2013 through 2020 by a single surgeon. Patient demographics, tumor and operative characteristics, and complications were retrieved from electronic medical records. Primary outcomes were postoperative complications and local recurrence rates.
Results
The final cohort included 117 patients with mean follow-up time of 2.60 + 1.78 years. Mean age was 69.84 + 8.77 years. Thirty-three (28.21%) of patients developed a seroma. Odds of seroma formation were mildly significant for skin spacing [OR: 1.18, 95% CI: (1.02-1.37)] and balloon fill volume [1.04 (1.00-1.08)], but not for age, BMI, diabetes, former or current smoking status, history of WBRT, tumor size, or balloon size. Three (2.6%) patients had local recurrence. Odds of local recurrence were mildly significant for increased tumor size [1.14 (1.04-1.24)] and not significant for any other covariates.
Conclusions
IORT exposure did not confer higher rates of complications and the local recurrence rate mirrored that of the general population undergoing lumpectomy and WBRT. This study demonstrates the need for equitable treatment options based on individual needs: IORT is a safe alternative to WBRT in certain subpopulations, especially those with physical, social, or personal limitations preventing participation in a 3- to 7-week time commitment of WBRT.
BurtLMYingJPoppeMMSunejaGGaffneyDK. Risk of secondary malignancies after radiation therapy for breast cancer: Comprehensive results. Breast. 2017;35:122-129. doi:10.1016/j.breast.2017.07.004
2.
HarrisEERSmallW. Intraoperative radiotherapy for breast cancer. Front Oncol. 2017;7:317. doi:10.3389/fonc.2017.00317
3.
SmithBDArthurDWBuchholzTA, et al.Accelerated partial breast irradiation consensus statement from the American society for radiation oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74:987-1001. doi:10.1016/j.ijrobp.2009.02.031
4.
Eldredge-HindyHBRosenbergALSimoneNL. Intraoperative radiotherapy for breast cancer: The lasting effects of a fleeting treatment. Int J Breast Cancer. 2014;2014:214325. doi:10.1155/2014/214325
5.
GobleRNDrukteinisJSLeeMCKhakpourNKilukJ V.LarongaC.Early experience with ultrasound features after intrabeam intraoperative radiation for early stage breast cancer. J Surg Oncol. 2014;109:751-755. doi:10.1002/jso.23581
StataCorp2021. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC.
8.
ArvoldNDTaghianAGNiemierkoA, et al.Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011;29:3885-3891. doi:10.1200/JCO.2011.36.1105
9.
BraunsteinLZTaghianAGNiemierkoA, et al.Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Res Treat. 2017;161:173-179. doi:10.1007/s10549-016-4031-5
10.
GuenziMBonzanoECorvòR, et al.Comparison of local recurrence among early breast cancer patients treated with electron intraoperative radiotherapy vs hypofractionated photon radiotherapy an observational study. Front Oncol. 2018;8:207. doi:10.3389/fonc.2018.00207
11.
PinderSEThompsonAMWesserlingJ. Low-risk DCIS. What is it? Observe or excise?Virchows Arch. 2022;480:21-32. doi:10.1007/s00428-021-03173-8
12.
RakovitchEPignolJPHannaW, et al.Significance of multifocality in ductal carcinoma in situ: Outcomes of women treated with breast-conserving therapy. J Clin Oncol. 2007;25:5591-5596. doi:10.1200/JCO.2007.11.4686
13.
HollandRVelingSHJavunacMHendriksJHCL. Histologic multifocality of tis, T1–2 breast carcinomas implications for clinical trials of breast‐conserving surgery. Cancer. 1985;56:979. doi:10.1002/1097-0142(19850901)56:5<979::aid-cncr2820560502>3.0.co;2-n
14.
CowellCFWeigeltBSakrRA, et al.Progression from ductal carcinoma in situ to invasive breast cancer: Revisited. Mol Oncol. 2013;7:859-869. doi:10.1016/j.molonc.2013.07.005
15.
FalcoMMasojćBRollaM, et al.Risk factors for seroma evacuation in breast cancer patients treated with intraoperative radiotherapy. Rep Pract Oncol Radiother. 2016;21:225-231. doi:10.1016/j.rpor.2016.03.003
16.
TuschyBBerlitSRomeroS, et al.Clinical aspects of intraoperative radiotherapy in early breast cancer: Short-term complications after IORT in women treated with low energy x-rays. Radiat Oncol. 2013;8:95. doi:10.1186/1748-717X-8-95
17.
KhanAJArthurDViciniF, et al.Six-year analysis of treatment-related toxicities in patients treated with accelerated partial breast irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial. Ann Surg Oncol. 2012;19:1477-1483. doi:10.1245/s10434-011-2133-1
18.
ShahCKhwajaSBadiyanS, et al.Brachytherapy-based partial breast irradiation is associated with low rates of complications and excellent cosmesis. Brachytherapy. 2013;12:278-284. doi:10.1016/j.brachy.2013.04.005
19.
ShahCBadiyanSBen WilkinsonJ, et al.Treatment efficacy with accelerated partial breast irradiation (APBI): Final analysis of the American society of breast surgeons MammoSite® breast brachytherapy registry trial. Ann Surg Oncol. 2013;20:3279-3285. doi:10.1245/s10434-013-3158-4
20.
LeeKQuilloADillonDSowardsKHatmakerADragunA. Acute toxicity and early cosmetic outcome in patients treated with multilumen balloon brachytherapy with skin spacing ≤7.0 millimeters. J Contemp Brachytherapy. 2012;4:8-13. doi:10.5114/jcb.2012.27946
21.
PatelPSYanWTrichterS, et al.Seroma is an expected consequence and not a complication of MammoSite brachytherapy. Breast J. 2011;17:498-502. doi:10.1111/j.1524-4741.2011.01127.x
22.
Ojeda-FournierHOlsonLKRochelleMHodgensBDTongEYasharCM. Accelerated partial breast irradiation and posttreatment imaging evaluation. Radiographics. 2011;31:1701-1716. doi:10.1148/rg.316115517
23.
VaidyaJSWenzFBulsaraM, et al.Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383:603-613. doi:10.1016/S0140-6736(13)61950-9
24.
VeronesiUOrecchiaRMaisonneuveP, et al.Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): A randomised controlled equivalence trial. Lancet Oncol. 2013;14:1269-1277. doi:10.1016/S1470-2045(13)70497-2
25.
FisherBAndersonSBryantJ, et al.Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233-1241. doi:10.1056/nejmoa022152
26.
AthasWFAdams-CameronMHuntWCAmir-FazliAKeyCR. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. J Natl Cancer Inst. 2000;92:269-271. doi:10.1093/jnci/92.3.269
27.
Ballard-BarbashRPotoskyALHarlanLCNayfieldSGKesslerLG. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst. 1996;88:716-726. doi:10.1093/jnci/88.11.716
28.
FarrowDCHuntWCSametJM. Geographic variation in the treatment of localized breast cancer. N Engl J Med. 1992;326:1097-1101. doi:10.1056/nejm199204233261701
29.
DolanJTGranchiTSMillerCCBrunicardiFC. Low use of breast conservation surgery in medically indigent populations. Am J Surg. 1999;178:470-474. doi:10.1016/S0002-9610(99)00226-3
30.
LindPARMGagliardiGWennbergBFornanderT. A descriptive study of pulmonary complications after postoperative radiation therapy in node-positive stage II breast cancer. Acta Oncol (Madr). 1997;36:509-515. doi:10.3109/02841869709001307
31.
Blom GoldmanUSvaneGAndersonMWennbergBLindP. Long-term functional and radiological pulmonary changes after radiation therapy for breast cancer. Acta Oncol (Madr). 2014;53:1373-1379. doi:10.3109/0284186X.2014.934967
32.
DarbySCEwertzMMcGaleP, et al.Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987-998. doi:10.1056/nejmoa1209825
33.
GrantzauTMellemkjærLOvergaardJ. Second primary cancers after adjuvant radiotherapy in early breast cancer patients: A national population based study under the Danish Breast Cancer Cooperative Group (DBCG). Radiother Oncol. 2013;106:42-49. doi:10.1016/j.radonc.2013.01.002
34.
SpaichSKrickebergSHetjensSWenzFGerhardtASütterlinM. Patient preferences regarding intraoperative versus external beam radiotherapy for early breast cancer and the impact of socio-demographic factors. Arch Gynecol Obstet. 2019;299:1121-1130. doi:10.1007/s00404-018-5025-9
35.
AlvaradoMDConollyJParkC, et al.Patient preferences regarding intraoperative versus external beam radiotherapy following breast-conserving surgery. Breast Cancer Res Treat. 2014;143:135-140. doi:10.1007/s10549-013-2782-9
